» Articles » PMID: 38001701

Lung Carcinoids: A Comprehensive Review for Clinicians

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2023 Nov 25
PMID 38001701
Authors
Affiliations
Soon will be listed here.
Abstract

Lung carcinoids are neuroendocrine tumors, categorized as typical or atypical carcinoids based on their histological appearance. While most of these tumors are slow-growing neoplasms, they still possess malignant potential. Many patients are diagnosed incidentally on chest X-rays or CT scans. Presenting symptoms include cough, hemoptysis, wheezing, dyspnea, and recurrent pneumonia. Endocrine symptoms, such as carcinoid syndrome or ectopic Cushing's syndrome, are rare. Surgery is the primary treatment and should be considered in all patients with localized disease, even when thoracic lymph node metastases are present. Patients with distant metastases may be treated with somatostatin analogues, chemotherapy, preferably temozolomide-based, mTOR inhibitors, or peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE. Most patients have an excellent prognosis. Poor prognostic factors include atypical histology and lymph node metastases at diagnosis. Long-term follow-up is mandatory since metastases may occur late.

Citing Articles

Impact of lymph node involvement in pulmonary carcinoids: a narrative review.

Dziedzic M, Cackowski M, Pawlica M, Gabrysz Z, Gofron K, Marjanski T Transl Lung Cancer Res. 2025; 13(12):3731-3740.

PMID: 39830772 PMC: 11736604. DOI: 10.21037/tlcr-24-446.


Unusual Presentation of Case of a Lung Carcinoid Tumor With Ectopic Adrenocorticotropic Secretion (EAS) Associated With Acute Weight Gain and Peripheral Edema.

Abouibrahim M, Rahman M, Zafar M, Berliti S, Hacikurt K, Dashora U Cureus. 2024; 16(7):e63619.

PMID: 39092370 PMC: 11290955. DOI: 10.7759/cureus.63619.


Perioperative Management of a Patient With Multiple Comorbidities Undergoing Lung Resection for Bronchopulmonary Carcinoid Complicated by SARS-CoV-2 Infection: A Case Report.

Sarridou D, Konstantinidou M, Boutou A, Mitos G, Karaiskos T Cureus. 2024; 16(4):e58310.

PMID: 38752045 PMC: 11095282. DOI: 10.7759/cureus.58310.

References
1.
Lou F, Sarkaria I, Pietanza C, Travis W, Roh M, Sica G . Recurrence of pulmonary carcinoid tumors after resection: implications for postoperative surveillance. Ann Thorac Surg. 2013; 96(4):1156-1162. DOI: 10.1016/j.athoracsur.2013.05.047. View

2.
Arrigoni M, WOOLNER L, BERNATZ P . Atypical carcinoid tumors of the lung. J Thorac Cardiovasc Surg. 1972; 64(3):413-21. View

3.
Gould V, Linnoila R, Memoli V, Warren W . Neuroendocrine components of the bronchopulmonary tract: hyperplasias, dysplasias, and neoplasms. Lab Invest. 1983; 49(5):519-37. View

4.
Fazio N, Buzzoni R, Delle Fave G, Tesselaar M, Wolin E, Van Cutsem E . Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis. Cancer Sci. 2017; 109(1):174-181. PMC: 5765303. DOI: 10.1111/cas.13427. View

5.
Ianniello A, Sansovini M, Severi S, Nicolini S, Grana C, Massri K . Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET. Eur J Nucl Med Mol Imaging. 2015; 43(6):1040-6. DOI: 10.1007/s00259-015-3262-8. View